HMNC Brain Health has appointed Maximilian Doebler as chief executive officer. He has held senior roles at HMNC since 2019, most recently as managing director and chief business officer, and becomes CEO as the company moves into its next phase of growth and development. The German neuroscience company recently closed a $50 million Series B financing and a European commercialisation partnership with MEDICE for its lead asset Ketabon (KET01).
Since joining HMNC, Dr Doebler has overseen the clinical progression of KET01, a treatment for depression, including the Phase 2 KET01-02 trial. Dr Doebler has a Master and Juris Doctor, Law from the University of Salzburg, Austria.
HMNC Brain Health announced the appointment on 21 September 2026.
Copyright 2026 Evernow Publishing Ltd.